Haopeng Yang

The paper establishes a PDX repository of large B-cell lymphoma models capturing clinical and molecular diversity, including post-CART19 progression cases.

The paper develops bivalent molecules that convert kinase inhibitors into activators of proapoptotic genes, achieving selective killing of DLBCL cells with low cytotoxicity.

The paper shows that CREBBP mutations disrupt chromatin loading dynamics and EP300 redundancy, creating zombie enzymes that impair enhancer activation in GC B-cells and lymphoma.

This study identifies subtype-specific and co-occurring genetic alterations across major B-NHL subtypes using targeted sequencing of 380 genes in 685 tumors.